David Hong, MD
Medical Oncology · Houston, TXNPI 1255439469
Payments from drug & device makers
Across 994 payments — averaging $31,760 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$13.1M
- Pfizer$10M
- Bayer$1.3M
- Mirati Therapeutics, Inc.$1M
- Deciphera Pharmaceuticals Inc.$803K
- Seagen Inc.$755K
- plus $4.7M from 24 others
Across 19 payments — averaging $2075.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$12K
- F. Hoffmann-la Roche AG$10K
- Eli Lilly$10K
- Amgen$3K
- Takeda Pharmaceuticals U.S.A., Inc.$3K
- Bayer$956
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 56 | $13,057,516 |
| Pfizer(2 entities) | 298 | $9,958,145 |
| Bayer | 104 | $1,325,211 |
| Mirati Therapeutics, Inc. | 49 | $1,010,874 |
| Deciphera Pharmaceuticals Inc. | 146 | $802,977 |
| Seagen Inc. | 45 | $755,071 |
| E.r. Squibb & Sons, L.L.C. | 12 | $713,684 |
| AbbVie | 154 | $704,791 |
| Exelixis Inc. | 10 | $590,377 |
| Eli Lilly | 9 | $432,647 |
| Novartis | 6 | $372,615 |
| Genentech, Inc. | 26 | $351,088 |
| Kyowa Kirin Pharmaceutical Development, Inc | 4 | $300,292 |
| Astrazeneca UK Limited | 5 | $261,445 |
| Beone Medicines USA, Inc. | 7 | $212,072 |
| Merck | 8 | $189,695 |
| AstraZeneca | 2 | $112,312 |
| Hoffmann-la Roche Limited | 5 | $103,387 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $84,845 |
| Incyte Corporation | 20 | $57,352 |
| Kyowa Kirin, Inc. | 2 | $55,206 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $39,006 |
| Daiichi Sankyo Inc. | 7 | $33,425 |
| F. Hoffmann-la Roche AG | 4 | $17,827 |
| Janssen Global Services, LLC | 2 | $13,800 |
| Alkermes, Inc. | 1 | $5,120 |
| Gilead | 2 | $3,412 |
| Sanofi | 1 | $3,136 |
| Takeda Pharmaceutical Company, Limited | 1 | $2,250 |
| Beigene USA, Inc. | 2 | $270 |
How this compares
$31,569,845 in reported general payments places this provider in the 95th percentile of 495 medical oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Houston
- Hagop KantarjianHouston$100.5M
- Timothy YapHouston$56.7M
- Yasir ElaminHouston$41.3M
- Guillermo Garcia-ManeroHouston$31.6M
- Jason WestinHouston$30.8M
- Lucia MasarovaHouston$29.7M
- Jordi Rodon AhnertHouston$28.1M
- Sarina Piha PaulHouston$26M
- Jenny ChangHouston$17.8M
- Hun LeeHouston$15.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.